Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80,235,145
-
Total 13F shares
-
67,207,302
-
Share change
-
+6,779,105
-
Total reported value
-
$2,701,742,064
-
Put/Call ratio
-
24%
-
Price per share
-
$40.20
-
Number of holders
-
161
-
Value change
-
+$296,832,171
-
Number of buys
-
97
-
Number of sells
-
58
Institutional Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q1 2024
As of 31 Mar 2024,
Kymera Therapeutics, Inc. - Common Stock (KYMR) was held by
161 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,207,302 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, Atlas Venture Life Science Advisors, LLC, BVF INC/IL, VANGUARD GROUP INC, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, Avoro Capital Advisors LLC, BlackRock Inc., and Artal Group S.A..
This page lists
161
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.